Sci Pharmtech (TPE:4119) Cyclically Adjusted Revenue per Share: NT$17.45 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4119 Sci Pharmtech Inc TPE:4119
67 GF Score
Price NT$49.15
GF Value NT$97.16
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Sci Pharmtech Cyclically Adjusted Revenue per Share?

Sci Pharmtech TPE:4119 -1.31% 67 Cyclically Adjusted Revenue per Share is NT$17.45 as of Dec. 2025. GuruFocus rates TPE:4119 with a GF Score™ of 67/100 and a GF Value™ of NT$97.16 (Possible Value Trap). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sci Pharmtech's adjusted revenue per share for the three months ended in Dec. 2025 was NT$2.962. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$17.45 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Sci Pharmtech's average Cyclically Adjusted Revenue Growth Rate was -3.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sci Pharmtech was 3.10% per year. The lowest was -1.60% per year. And the median was -0.05% per year.

As of today (2026-07-24), Sci Pharmtech's current stock price is NT$49.15. Sci Pharmtech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$17.45. Sci Pharmtech's Cyclically Adjusted PS Ratio of today is 2.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sci Pharmtech was 6.14. The lowest was 2.32. And the median was 4.49.


Sci Pharmtech  (TPE:4119) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sci Pharmtech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=49.15/17.45
=2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sci Pharmtech was 6.14. The lowest was 2.32. And the median was 4.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sci Pharmtech Cyclically Adjusted Revenue per Share Related Terms


Sci Pharmtech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sci Pharmtech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sci Pharmtech Cyclically Adjusted Revenue per Share Chart

Sci Pharmtech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.36 18.30 18.16 18.11 17.45

Sci Pharmtech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.11 18.11 17.84 17.63 17.45

TPE:4119 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sci Pharmtech Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sci Pharmtech's Cyclically Adjusted PS Ratio falls into.


TPE:4119
67GF Score
Sci Pharmtech Inc TPE:4119
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sci Pharmtech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sci Pharmtech's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=2.962/324.0540*324.0540
=2.962

Current CPI (Dec. 2025) = 324.0540.

Sci Pharmtech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 5.905 238.132 8.036
201606 4.783 241.018 6.431
201609 4.344 241.428 5.831
201612 2.374 241.432 3.186
201703 3.006 243.801 3.995
201706 2.609 244.955 3.451
201709 3.248 246.819 4.264
201712 3.019 246.524 3.968
201803 3.898 249.554 5.062
201806 4.850 251.989 6.237
201809 4.747 252.439 6.094
201812 4.261 251.233 5.496
201903 5.492 254.202 7.001
201906 5.504 256.143 6.963
201909 5.729 256.759 7.231
201912 4.725 256.974 5.958
202003 7.132 258.115 8.954
202006 6.655 257.797 8.365
202009 6.195 260.280 7.713
202012 4.565 260.474 5.679
202103 2.954 264.877 3.614
202106 1.648 271.696 1.966
202109 2.070 274.310 2.445
202112 1.246 278.802 1.448
202203 1.723 287.504 1.942
202206 1.481 296.311 1.620
202209 2.776 296.808 3.031
202212 2.199 296.797 2.401
202303 3.177 301.836 3.411
202306 2.919 305.109 3.100
202309 2.405 307.789 2.532
202312 2.529 306.746 2.672
202403 2.587 312.332 2.684
202406 3.284 314.175 3.387
202409 3.498 315.301 3.595
202412 3.347 315.605 3.437
202503 3.006 319.799 3.046
202506 3.098 322.561 3.112
202509 2.199 324.800 2.194
202512 2.962 324.054 2.962

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$17.45 mean?
Sci Pharmtech (TPE:4119) has a Cyclically Adjusted Revenue per Share of NT$17.45 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sci Pharmtech and its competitors.
Is Sci Pharmtech's Cyclically Adjusted Revenue per Share too high?
Sci Pharmtech's current Cyclically Adjusted Revenue per Share is NT$17.45. Overall, Sci Pharmtech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Sci Pharmtech's Cyclically Adjusted Revenue per Share of NT$17.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sci Pharmtech and its competitors. Sci Pharmtech's current Cyclically Adjusted Revenue per Share is NT$17.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Possible Value Trap. The stock's GF Value™ is NT$97.16, compared to a current price of NT$49.15 — trading 49.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$17.45. Sci Pharmtech's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Cyclically Adjusted Revenue per Share is NT$17.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sci Pharmtech (TPE:4119) Overvalued in 2026?

Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued. The current stock price of NT$49.15 is trading 49.4% below its estimated GF Value™ of NT$97.16. GuruFocus considers Sci Pharmtech to be Possible Value Trap.

Key valuation signals for TPE:4119:

  • Cyclically Adjusted Revenue per Share: NT$17.45
  • GF Value™: NT$97.16 vs. price of NT$49.15 (49.4% below fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sci Pharmtech Business Description

Address No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
67GF Score

Get the complete analysis for TPE:4119

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.15
Price
NT$97.16
GF Value